Kühnle, Ingrid

[["dc.bibliographiccitation.firstpage","3555"],["dc.bibliographiccitation.issue","12"],["dc.bibliographiccitation.journal","Cancers"],["dc.bibliographiccitation.volume","12"],["dc.contributor.author","Hell, Anna K."],["dc.contributor.author","Kühnle, Ingrid"],["dc.contributor.author","Lorenz, Heiko M."],["dc.contributor.author","Braunschweig, Lena"],["dc.contributor.author","Lüders, Katja A."],["dc.contributor.author","Bock, Hans Christoph"],["dc.contributor.author","Kramm, Christof M."],["dc.contributor.author","Ludwig, Hans Christoph"],["dc.contributor.author","Tsaknakis, Konstantinos"],["dc.date.accessioned","2021-04-14T08:27:47Z"],["dc.date.available","2021-04-14T08:27:47Z"],["dc.date.issued","2020"],["dc.identifier.doi","10.3390/cancers12123555"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/82404"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-399"],["dc.publisher","MDPI"],["dc.relation.eissn","2072-6694"],["dc.rights","https://creativecommons.org/licenses/by/4.0/"],["dc.title","Spinal Deformities after Childhood Tumors"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","56"],["dc.bibliographiccitation.journal","Diagnostic Pathology"],["dc.bibliographiccitation.volume","11"],["dc.contributor.author","Schildhaus, Hans-Ulrich"],["dc.contributor.author","Lokka, Suvi"],["dc.contributor.author","Fenner, Werner"],["dc.contributor.author","Kuester, Jens"],["dc.contributor.author","Kuehnle, Ingrid"],["dc.contributor.author","Heinmoeller, Ernst"],["dc.date.accessioned","2018-11-07T10:12:34Z"],["dc.date.available","2018-11-07T10:12:34Z"],["dc.date.issued","2016"],["dc.description.abstract","Background: Embryonal rhabdomyosarcoma of the prostate in an adult is a very rare event with only a few cases published. Diagnosis usually occurs with advanced disease frequently already with metastatic spread. In adults prognosis is very poor, therefore early diagnosis is crucial. To date, only three cases of spindle cell subtype of embryonal rhabdomyosarcoma of the prostate in an adult have been published. Case presentation: We report an additional case of prostatic spindle cell embryonal rhabdomyosarcoma subtype in an adult. Conclusions: We discuss relevant clinicopathological features of spindle cell embryonal rhabdomyosarcoma of the prostate in adult patients in the context of the literature."],["dc.identifier.doi","10.1186/s13000-016-0507-1"],["dc.identifier.isi","000379299000001"],["dc.identifier.pmid","27357857"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/13382"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/40263"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Biomed Central Ltd"],["dc.relation.issn","1746-1596"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Spindle cell embryonal rhabdomyosarcoma of the prostate in an adult patient - case report and review of clinicopathological features"],["dc.type","review"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1948"],["dc.bibliographiccitation.issue","12"],["dc.bibliographiccitation.journal","Haematologica"],["dc.bibliographiccitation.lastpage","1955"],["dc.bibliographiccitation.volume","98"],["dc.contributor.author","Rensing-Ehl, Anne"],["dc.contributor.author","Janda, Ales"],["dc.contributor.author","Lorenz, Myriam Ricarda"],["dc.contributor.author","Gladstone, Beryl P."],["dc.contributor.author","Fuchs, Ilka"],["dc.contributor.author","Abinun, Mario"],["dc.contributor.author","Albert, Michael"],["dc.contributor.author","Butler, Karina"],["dc.contributor.author","Cant, Andrew"],["dc.contributor.author","Cseh, Anna-Maria"],["dc.contributor.author","Ebinger, Martin"],["dc.contributor.author","Goldacker, Sigune"],["dc.contributor.author","Hambleton, Sophie"],["dc.contributor.author","Hebart, Holger F."],["dc.contributor.author","Houet, Leonora"],["dc.contributor.author","Kentouche, Karim"],["dc.contributor.author","Kuehnle, Ingrid"],["dc.contributor.author","Lehmberg, Kai"],["dc.contributor.author","Mejstrikova, Ester"],["dc.contributor.author","Niemeyer, Charlotte"],["dc.contributor.author","Minkov, Milen"],["dc.contributor.author","Neth, Olaf"],["dc.contributor.author","Dueckers, Gregor"],["dc.contributor.author","Owens, Stephan"],["dc.contributor.author","Roesler, Joachim"],["dc.contributor.author","Schilling, Freimut H."],["dc.contributor.author","Schuster, Volker"],["dc.contributor.author","Seidel, Markus G."],["dc.contributor.author","Smisek, Petr"],["dc.contributor.author","Sukova, Martina"],["dc.contributor.author","Svec, Peter"],["dc.contributor.author","Wiesel, Thomas"],["dc.contributor.author","Gathmann, Benjamin"],["dc.contributor.author","Schwarz, Klaus"],["dc.contributor.author","Vach, Werner"],["dc.contributor.author","Ehl, Stephan"],["dc.contributor.author","Speckmann, Carsten"],["dc.date.accessioned","2018-11-07T09:16:59Z"],["dc.date.available","2018-11-07T09:16:59Z"],["dc.date.issued","2013"],["dc.description.abstract","Clinical and genetic heterogeneity renders confirmation or exclusion of autoimmune lymphoproliferative syndrome difficult. To re-evaluate and improve the currently suggested diagnostic approach to patients with suspected FAS mutation, the most frequent cause of autoimmune lymphoproliferative syndrome, we prospectively determined 11 biomarkers in 163 patients with splenomegaly or lymphadenopathy and presumed or proven autoimmune cytopenia(s). Among 98 patients sequenced for FAS mutations in CD3(+)TCR alpha/CD4(-)CD8(-) \"double negative\" T cells, 32 had germline and six had somatic FAS mutations. The best a priori predictor of FAS mutations was the combination of vitamin B12 and soluble FAS ligand (cut-offs 1255 pg/mL and 559 pg/mL, respectively), which had a positive predictive value of 92% and a negative predictive value of 97%. We used these data to develop a web-based probability calculator for FAS mutations using the three most discriminatory biomarkers (vitamin B12, soluble FAS ligand, interleukin-10) of the 11 tested. Since more than 60% of patients with lymphoproliferation and autoimmune cytopenia(s) in our cohort did not harbor FAS mutations, 15% had somatic FAS mutations, and the predictive value of double-negative T-cell values was rather low (positive and negative predictive values of 61% and 77%, respectively), we argue that the previously suggested diagnostic algorithm based on determination of double-negative T cells and germline FAS sequencing, followed by biomarker analysis, is not efficient. We propose vitamin B12 and soluble FAS ligand assessment as the initial diagnostic step with subsequent decision on FAS sequencing supported by a probability-calculating tool."],["dc.identifier.doi","10.3324/haematol.2012.081901"],["dc.identifier.isi","000328545500024"],["dc.identifier.pmid","23850805"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/10939"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/28059"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Ferrata Storti Foundation"],["dc.relation.issn","0390-6078"],["dc.rights","CC BY 3.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/3.0"],["dc.title","Sequential decisions on FAS sequencing guided by biomarkers in patients with lymphoproliferation and autoimmune cytopenia"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","984"],["dc.bibliographiccitation.issue","9"],["dc.bibliographiccitation.journal","Journal der Deutschen Dermatologischen Gesellschaft"],["dc.bibliographiccitation.lastpage","993"],["dc.bibliographiccitation.volume","18"],["dc.contributor.author","Hartmann, Franziska"],["dc.contributor.author","Lockmann, Anike"],["dc.contributor.author","Himpel, Okko"],["dc.contributor.author","Kühnle, Ingrid"],["dc.contributor.author","Hensen, Janina"],["dc.contributor.author","Schön, Michael P."],["dc.contributor.author","Thoms, Kai‐Martin"],["dc.date.accessioned","2021-04-14T08:22:56Z"],["dc.date.available","2021-04-14T08:22:56Z"],["dc.date.issued","2020"],["dc.description.abstract","Summary Background and aims Infantile hemangiomas can be successfully treated by both systemic propranolol and neodymium:YAG (Nd:YAG)‐dye laser combination therapy. In this retrospective study, the efficacy and safety of sequential and parallel therapy of complicated hemangiomas treated with both methods were evaluated. Patients and methods 30 children with 48 complicated hemangiomas were treated with propranolol and Nd:YAG‐dye laser combination therapy. Using photo comparison, the percentage remission rate was evaluated by three investigators on a four‐step scale (I: 0–25 %, II: 26–50 %, III: 51–75 % and IV: 76–100 %). Results Eleven children received propranolol and laser therapy in parallel (A), twelve children received laser therapy after propranolol (B) and seven children received propranolol after laser therapy (C). Due to emigration abroad, one child was lost to follow‐up. A strong improvement (IV) was observed in 23/29 (79.3 %) of all treated children (A: 90.9 %, B 75 %, C 66.7 %). The mean duration of propranolol therapy in all children was 8.6 months (A: 8.9 months, B: 8.2 months, C: 8.9 months). On average, 2.33 laser treatments were performed per hemangioma (A: 1.95, B: 3.2, C: 1.91). Serious side effects caused by propranolol and laser therapy were not observed. Conclusions Propranolol and Nd:YAG‐dye laser combination therapy can be used sequentially or in parallel safely and effectively. They complement each other in a meaningful manner."],["dc.identifier.doi","10.1111/ddg.14184"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/80739"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-399"],["dc.relation.eissn","1610-0387"],["dc.relation.issn","1610-0379"],["dc.rights","This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made."],["dc.title","Combination therapy of oral propranolol and combined Nd:YAG/pulsed dye laser therapy in infantile hemangiomas: a retrospective analysis of 48 treated hemangiomas in 30 children"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]